LGVN
Longeveron Inc. Common Stock
stockNASDAQ
longeveron llc is a leading global regenerative medicine company developing innovative cellular therapeutics for chronic life-threatening diseases. our lead investigational product candidate (lmsc) is based on a specialized cell known as a mesenchymal stem cell that is derived from the bone marrow of healthy young adult donors. our allogeneic, 'off-the-shelf' product is under investigation for chronic conditions of the elderly, and other life- threatening diseases, for which no approved therapeutics currently exist: • aging frailty syndrome • alzheimer's disease • hypoplastic left heart syndrome • the metabolic syndrome
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 1.61 | 2026-10-26 | +6.54% | 4.650 |
| 1M | 2.59 | 2026-10-01 | -33.98% | 2.063 |
| 3M | 7.02 | 2026-07-31 | -75.62% | -1.090 |
| 6M | 8.51 | 2026-05-01 | -79.91% | 0.427 |
| 1Y | 8.34 | 2025-10-31 | -79.49% | 0.619 |
| 2Y | 20.30 | 2024-11-01 | -91.58% | — |
| 5Y | 349.00 | 2021-11-01 | -99.51% | 1.149 |
Longeveron Inc. Common Stock (NASDAQ:LGVN) stock price today is $1.71, and today's volume is 80,814. LGVN is down 2.286% today. The 30 day average volume is 84,310. LGVN market cap is $5.45M with 3.19M shares outstanding.